Original Research Article

Antimicrobial susceptibility profiles of *Pseudomonas aeruginosa* isolates from patients attending health care facilities, Ebonyi Sate, Nigeria

ABSTRACT

Aim: To assess age group related level of infection and antimicrobial susceptibility profiles of *Pseudomonas aeruginosa* isolates from wound infection.

Study Design: This is a cross sectional study conducted among patients suspected of having wound infection to determine age group related level of infection and antimicrobial susceptibility profile of the *P. aeruginosa* isolates.

Place and Duration of Study: The study was conducted between May, 2015 and June, 2016 at the Microbiology Laboratory of Akanu Ibiam Federal Polytechnic, Unwana, Ebonyi State, Nigeria.

Methodology: A total of 165 wound swabs were analysed for the presence of *P. aeruginosa.* Standard microbiology laboratory tests were used to isolate and identify the isolates. Antibiotic susceptibility testing of the isolates were carried out using the disc diffusion method.

Results: A total of 56 (33.94 %) *P. aeruginosa* isolates were identified. The age group 31 – 40 years recorded the highest number 28 (50.00 %) of *P. aeruginosa* infection. Within this age group, females 15 (51.72 %) were slightly more infected than males 13 (48.15 %). In the tertiary hospital (MMH), the highest sensitivity was seen to ofloxacin 32 (78.05 %) followed by ciprofloxacin, 29 (70.73 %) and ceftazidime, 26 (63.41 %). The number of the isolates resistant to amoxicillin/clavulanate, cefixime and cefuroxime were 34 (82.93 %), 26 (63.41%) and 23 (56.10 %) respectively. The number of sensitive *P. aeruginosa* from the teaching hospital (FETHA) to ofloxacin and ciprofloxacin were 9 (60.00 %) and 8 (53.33 %) respectively. In FETHA, the isolates showed the highest resistance to amoxicillin/clavulanate 14 (93.33 %) and cefixime 12 (80. 00 %). Exactly, 32 (57.14 %) of *P. aeruginosa* isolates were found to be multidrug resistant (MDR). Regular monitoring of antimicrobial susceptibility profile is essential to guide the physicians in drug prescription against *P. aeruginosa* strains.

Keywords: Susceptibility, Infection, P. aeruginosa, Multidrug resistance.

1. INTRODUCTION

Wound infection is universal and the bacterial type varies with geographical location, resident flora of the skin, clothing at the site of wound, time between wound and examination [1]. The development of wound infection depends on the integrity and protective function of the skin [1]. Many bacteria pathogens are involved in wound infection [2].

P. aeruginosa can be found in most environments including soil, water and various types of vegetation. The organism is a clinically important pathogen, responsible for a variety of systemic infections such as urinary tract infections, respiratory system infections, gastrointestinal infections, dermatitis, bacteremia, soft tissue infections, bone and joint infections [3]. *P. aeruginosa* causes infection in immunocompromised patients such as those suffering from burn wounds or receiving cancer chemotherapy [4]. It is a major nosocomial pathogen, particularly dangerous to cystic fibrosis patients [5].

This organism is resistant to many antibacterial drugs [6]. Multidrug-resistant *P. aeruginosa* phenotype is defined as resistant to one anti-microbial agent in three or more anti-pseudomonal anti-microbial classes (carbapenems, fluoroquinolones, penicillins/cephalosporins and aminoglycosides) [7, 8]. MDR *P. aeruginosa* is an important public health issue because the organism is inherently resistant to many drug classes and is able to acquire resistance to all effective antimicrobial drugs [9]. Multidrug-resistant *P. aeruginosa* develops resistance by various mechanisms like multidrug resistance efflux pumps, biofilm formation, production of β-lactamases and aminoglycoside modifying enzymes [8]. Broad-spectrum anti-pseudomonal drugs such as imipenem, ceftazidime, amikacin have been recommended for treatments of infections caused by multiple drug resistant *P. aeruginosa* [10]. However, resistance to one or more of these anti-pseudomonal drugs during therapy has been widely observed.

The alarming rate of resistance in bacteria pathogens raises concern for the effectiveness of antibiotic therapy [11]. The spread of multidrug resistant pathogens is a real threat to public health and a major concern for infection control practitioners globally [12]. This spread has paved way for the re-emergence of previously controlled diseases and a high frequency of opportunistic and chronic infection cases in developing countries like Nigeria [12].

This study aims at assessing age group related level of infection and antimicrobial susceptibility profiles of *P. aeruginosa* isolates from wound infection.

2. MATERIALS AND METHODS

2.1 Study Area

One tertiary hospital (MMH) and one teaching hospital (FETHA) in Ebonyi State, Nigeria was used for this study. These hospitals were selected because they receive large number of patients seeking medical attention and also serve as referral centre for the state and neighbouring states.

2.2 Sample Collection

A total of 165 wound swabs were collected from patients aged 11 years and above. No specimen was got from the age group 0 -10 years. All the wound swabs collected at the hospitals were inoculated into 10 ml cooked meat broth and incubated at 37 ^{o}C for 48 hours [13].

2.3 Isolation of Bacteria

A loopful of the organisms growing in the cooked meat broth above was inoculated onto Cetrimide agar plates using the streaking technique. The inoculated Petri dishes were incubated at 37 ^{o}C for 24 hours [14]. Suspected discrete colonies of *P. aeruginosa* that appeared green on cetrimide agar were inoculated into nutrient broth and nutrient agar slants and incubated at 37 ^{o}C for 24 hours. The organisms were confirmed by adopting standard microbiological procedure which includes: colony morphology, Gram stain reaction and biochemical reaction such as catalase test, indole test, motility test, citrate utilization test, oxidase test, triple sugar iron agar test and urease test.

2.4 Antibiotic Susceptibility Testing

In vitro **a**ntibiotic susceptibility testing of the isolates were carried out using the disc diffusion method as recommended by the Clinical and Laboratory Standard Institute [15]. The antibiotic disc used include: Ceftazidime 30 µg, Cefuroxime 30 µg, Gentamycin 10 µg, Cefixime 5 µg, Ofloxacin 5 µg, Amoxycillin/clavulanate 30 µg, and Ciprofloxacin 5 µg (Abtek Biologicals Ltd, Liverpool, U.K). A sterile Pasteur pipette was used to drop 0.2 ml of the standardized inoculum equivalent of 0.5 McFarland turbidity standards (1.0 x10^{8} cfu/ml) on the surface of dry Mueller-Hinton agar. The inoculum was evenly spread

using Hockey stick shaped glass rod. The agar was left for about 10 minutes for the inoculum to dry and thereafter, antibiotic discs were aseptically placed on the surface of the inoculated Mueller-Hinton agar plate using heat sterilized forceps. They were incubated at 37 ^{o}C for 18-24 hours. The diameter of zones of inhibition for each antibiotic was measured in millilitre and compared with values provided by the Clinical and Laboratory Standard Institute [15].

2.5 Statistical Analysis

Statistical analysis was carried using the statistical package for social sciences (SPSS) version 15. $P < 0.05$ was considered significant.

2. RESULTS AND DISCUSSION

Out of 165 wound swabs analysed, 56 (33.94 %) *P. aeruginosa* isolates were obtained (Table 1). The most frequent isolates of *P. aeruginosa* were from trauma 39 (44.32 %) followed by burn wound 3 (25.00 %).

Table 1: Distribution *of P. aeruginosa* from wound swabs

Type of wound	**Number**	**Number of bacterial isolates obtained**	**Percentage bacterial isolates**
Burn wound	12	3	25.00
Abscess	65	14	21.54
Trauma	88	39	44.32
Total	**165**	**56**	**33.94**

The age group 31 – 40 years recorded the highest number 28 (50.00 %) of *P. aeruginosa* infection. (Fig. 1). Within this age group, females 15 (51.72 %) were slightly more infected than males 13 (48.15 %).



Figure 1: Mean age group and gender distribution of *P. aeruginosa* isolates from wound swabs.

Key: % = Percentage in bracket

Antibiotic susceptibility profile of *P. aeruginosa* from MMH is as shown in Table 2. The highest sensitivity was seen to ofloxacin 32 (78.05 %) followed by ciprofloxacin, 29 (70.73 %) and ceftazidime, 26 (63.41 %). The number of the isolates resistant to amoxicillin/clavulanate, cefixime and cefuroxime were 34 (82.93 %), 26 (63.41%) and 23 (56.10 %) respectively.

Table 2: Antibiotic Susceptibility Profile of *P. aeruginosa* isolates from Wound swabs, MMH.

Antibiotic	**Disc Content**	**Number of sensitive Isolates (%)**	**Number of Intermediate Isolates (%)**	**Number of Resistant Isolates (%)**
Ceftazidime	30 µg	26 (63.41)	4 (9.76)	11 (26.83)
Cefuroxime	30 µg	13 (31.71)	5 (12.20)	23(56.10)
Gentamycin	10 µg	15 (36.59)	5 (12.20)	21 (51.22)
Cefixime	5 µg	6 (14.63)	9 (21.95)	26 (63.41)
Ofloxacin	5 µg	32 (78.05)	0 (0.00)	9 (21.95)
Amoxicillin/ Clavulanate	30 µg	3 (7.32)	4 (9.76)	34 (82.93)
Ciprofloxacin	5 µg	29 (70.73)	3 (7.32)	9 (21.95)

Key: % = Percentage in bracket; MMH = Code of tertiary hospital used

The number of sensitive *P. aeruginosa* from FETHA to ofloxacin and ciprofloxacin were 9 (60.00 %) and 8 (53.33 %) respectively (Table 3). The isolates showed the highest resistance to amoxicillin/clavulanate 14 (93.33 %) and cefixime 12 (80. 00 %).

Table 3: Antibiotic Susceptibility Profile of *P. aeruginosa* isolates from Wound swabs, FETHA.

Antibiotic	**Disc Content**	**Number of sensitive Isolates (%)**	**Number of Intermediate Isolates (%)**	**Number of Resistant Isolates (%)**
Ceftazidime	30 µg	6 (40.00)	1 (6.67)	8 (53.33)
Cefuroxime	30 µg	5 (33.33)	1 (6.67)	9(60.00)
Gentamycin	10 µg	4 (26.67)	2 (13.33)	9(60.00)
Cefixime	5 µg	2 (13.33)	1 (6.67)	12 (80.00)
Ofloxacin	5 µg	9 (60.00)	1 (6.67)	5 (33.33)
Amoxicillin/ Clavulanate	30 µg	1 (6.67)	0 (0.00)	14 (93.33)
Ciprofloxacin	5 µg	8 (53.33)	0 (0.00)	7 (46.67)

Key: % = Percentage in bracket; FETHA = Code of tertiary hospital used

Exactly, 57.14 % *P. aeruginosa* isolates from the two hospitals were found to be multidrug resistant. (Table 4). The prevalence was slightly higher in MMH (58. 54 %) than FETHA (53.33 %).

Table 4: Prevalence of MDR Isolates of *P. aeruginosa* from Wound swabs.

Hospital	Total No. of *P. aeruginosa* Isolates	Number of MDR *P. aeruginosa* Isolates	Percentage of MDR *P. aeruginosa* Isolates
MMH	41	24	58.54
FETHA	15	8	53.33
Total	56	32	57.14

Key: MDR = Multidrug Resistant

P. aeruginosa is known to be associated with wound infections. The result of this study is in contrast with the reports of Garba et al. [2] who isolated 11 % of *P. aeruginosa* from wounds of patients attending Ahmadu Bello University Teaching Hospital, Zaria, Nigeria. Also, Hyder et al. [16] and Mama et

al. [17] reported a lower prevalence of 6 (3.95 %) and 11 (8 %) respectively. Similarly, Ezebialu et al. [18] isolated 27.3 % *P. aeruginosa* from wounds in Enugu, which is slightly lower than the 33.94 % recorded in this study. The findings of this study is similar to the reports of Nwachukwu et al. [19] and Anupurba et al. [1] that isolated 32.90 % and 32 % *P. aeruginosa* respectively from wound swabs.

In a similar study carried out by Kirecci and Kareem [20], the age group mostly infected with *P. aeruginosa* was 41 – 60 years representing 45.33 %. Their finding differ from the present study where the age group 31 – 40 years (50.00 %) recorded the highest number of *P. aeruginosa* infection. Rajat et al. [21] reported isolation rate of 29 % in the age group of 31–45 years which is similar to our study and that done by Chander and Raza [22] that had 20% in age group of 21–40 years.

P. aeruginosa has been reported to have innate resistance to several antibiotics due to the presence of lipopolysaccharide in the outer membrane [16]. In Nigeria, the trend in resistance phenotype of *P. aeruginosa* to commonly prescribed antibiotics in various hospitals is increasing since the last decade [10]. In line with the present study, Jombo *et al.* [23] and Garba *et al*. [2] reported a high resistance to amoxicillin/clavulanate 100 % and 81.8 % respectively among *P. aeruginosa* isolates from urine and wound swabs. Rajeevan *et al*. [24] found 40 % and 20 % resistance to ceftazidime and gentamycin respectively. This is low compared the finding of this study in FETHA with ceftazidime and gentamycin resistance of 53.33 % and 60.00 % respectively. In MMH, the resistance to gentamycin 51.22 % was high compared to 20 % resistance reported by Rajeevan *et al*. [24]. Ahmed *et al*. [8] reported a high (91 %) level resistance to ceftazidime. In comparison to the present study from the two hospitals. Hyder *et al*. [16] recorded a higher level of resistance to gentamycin 70.83 % and a lower level of resistance to ciprofloxacin 31.25 % in Hlla Teaching hospital, Babylon. The resistance observed against Ceftazidime is worrisome, being among the broad-spectrum anti-pseudomonal drugs recommended for treatments of infections caused by MDR *P. aeruginosa* [10]. High resistance of the isolates to antibiotics may be due to the practice of self-medication, lack of diagnostic laboratory services or unavailability of guideline regarding the selection of drugs, thereby leading to inappropriate use of antibiotics [17].

Various researchers have reported lower rates of MDR *P. aeruginosa* in their study. Ahmed et al. [8] detected a slightly low prevalence rate 52 % compared to this study in patients with nosocomial infections at a University hospital, Egypt. In Iran, Zahra and Moniri [25] reported 30 % prevalence of MDR

P. aeruginosa. Siveraj et al. [26] reported 12 % MDR among *P. aeruginosa* isolates from India. In Abeokuta, Nigeria, Okonko *et al*. [27] reported multidrug resistant to 5 antibiotics (ampicillin, chloramphenicol, cotrimoxazole, nitrofuratoin and tetracycline) by *P. aeruginosa.* The level of MDR recorded in this study shows that *P. aeruginosa* can develop resistance to many antibacterial. *P. aeruginosa* can develop resistance to many antibacterials both through the resistance genes on extrachromosomal genetic elements and through mutational processes [28].

3. CONCLUSION

In this study, 56 (33.94 %) isolates of *P. aeruginosa* were obtained from the wound swabs analyzed. The age group mostly infected with *P. aeruginosa* was 31 – 40 years. The *P. aeruginosa* strains were more sensitive to ofloxacin while they showed the highest resistance to amoxicillin/clavulanate. Exactly, 57.14 % *P. aeruginosa* isolates were found to be multidrug resistant. A regular monitoring of antimicrobial susceptibility profile is essential to guide the physicians in prescribing right drugs and prevent the emergence of multidrug resistance strains of *P. aeruginosa*.

COMPETING INTEREST

Authors have declared that competing interest do not exist.

CONSENT

All authors declare that written informed consent was obtained from the patients for publication of this case report. A copy of the written consent is available for review by the Editorial office/Chief Editor/Editorial Board members of this journal.

REFERENCES

1. Anupurba S, Bhattacharjee A, Garg A, Sen MR. Antimicrobial susceptibility of *Pseudomonas aeruginosa* isolated from wound infections. Indian Journal of Dermatology, 2010; 51: 286-288.

2. Garba I, Lusa YH, Bawa E, Tijjani MB, Aliyu MS, Zango UU, Raji MIO. Antibiotics Susceptibility Pattern of *Pseudomonas aeruginosa* isolated from Wounds in Patients Attending Ahmadu Bello University Teaching Hospital, Zaria, Nigeria. Nigerian Journal of Basic and Applied Science, 2012; 20(1):32-34. http://www.ajol.info/index.php/njbas/index

3. Nasreen M, Sarker A, Malek MA, Ansaruzzaman MD, Rahman M. Prevalence and Resistance Pattern of *Pseudomonas aeruginosa* Isolated from Surface Water. Advances in Microbiology, 2015; **5**: 74-81.http://dx.doi.org/10.4236/aim.2015.51008

4. Abouelfetouch AY, Moussa NK. Enhancement of antimicrobial activity of four classes of antimicrobials combined with garlic. Asian Journal of Plant Science, 2012. DOI: 10.3920/ajps.2012.

5. Jayaraman P, Meena KS, Chu SL, Thean HT, Kishore RS. Activity and interactions of antibiotic and phytochemical combinations against *Pseudomonas aeruginosa* in vitro. International Journal of Biological Sciences, 2010; 6 (6): 556-568

6. Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y. *Pseudomonas aeruginosa*: resistance and therapeutic options at the turn of the new millennium. Clinical Microbiology of Infection, 2007; 13: 560-578.

7. Magiorakos AP. Multidrug-Resistant (MDR), Extensively Drug Resistant (XDR) and Pandrug-1 Resistant (PDR) Bacteria in Healthcare Settings. Expert Proposal for a Standardized International Terminology, 2011. Available online at www.escmid.org.

8. Ahmed BM, Wafaa AZ, Ghada RH, Aza ZL, Rasha G. Prevalence of Multidrug-Resistant *Pseudomonas aeruginosa* in Patients with Nosocomial Infections at a University Hospital in Egypt, with Special Reference to Typing Methods,". Journal of Virology and Microbiology, vol. 2013. Article ID 290047, 13 pages. DOI: 10.5171/2013.290047

9. Gad GF, El- Domany RA, Zaki S, and Ashour HM. Characterization of *Pseudomonas aeruginosa* Isolated from Clinical and Environmental Samples in Minia, Egypt: Prevalence, Antibiogram and Resistance Mechanisms, Journal of Antimicrobial Chemotherapy, 2007; 60: 1010–1017

10. Odumosu BT, Bolanle AA, Dada-Adegbola H, Ram C. Multidrug Resistant *Pseudomonas aeruginosa* From Southwest Nigeria Hospitals. International Journal of Pharmaceutical Science and Review Research, 2012; 15(2): 11-15

11. Nmema EE. Peculiar pattern of antibiotic resistance in bacteria isolated from various sources in South-East Nigeria and the implications in health and economy. Journal of Applied Science and Environment, 2013;17 (4):529-534

12. Vishal G, Trivedi NA. In vitro evaluation of antimicrobial effect of fresh garlic extract and its interaction with conventional antimicrobials against *Escherichia coli* isolates. International Journal of Current Research and Reviews, 2012; 05 (1):106-114

13. Saana SBBM, Adu F, Agyare C, Gbedema CY, Boamah VE, George DF. Antibiotic resistance patterns of strains of *Staphylococcus aureus* isolated from patients in three hospitals in Kumasi, Ghana. *Journal of Bacteriology Research*, 2013; 5(3): 35-40. DOI: 10.5897/JBR2012.0081

14. Betty F, Daniel S, Alice W. Bailey & Scott's Diagnostic Microbiology. 12th edition. Elsevier Inc; New York; 2007; 322-325.

15. CLSI. Performance standards for antimicrobial susceptibility testing; twentieth informational supplement CLSI document M100–S20 Wayne, PA. 2012.

16. Hyder H, Tarrad JK, Banyan HA. Isolation of *Psudomonas aeruginosa* from clinical and environmental samples, and analysis of its antibiotic resistant spectrum at Hilla Teaching Hospital. Medical Journal of Babylon, 2011; 8(4): 618-624.

17. Mama M, Abdissa A, Sewunet T. Antimicrobial susceptibility pattern of bacterial isolates from wound infection and their sensitivity to alternative topical agents at Jimma University Specialized Hospital, South-West Ethiopia. Annals of Clinical Microbiology and Antimicrobials, 2014; 13:14. http://www.ann-clinmicrob.com/content/13/1/14

18. Ezebialu CU, Chukwurah EI, Ezebialu IU. Bacterial pathogens associated with wound infections at National Orthopaedic Hospital, Enugu. Nigerian Journal of Microbiology, 2010; 24(1): 1987-1992.

19. Nwachukwu NC, Orji FA, Okike UM. Antibiotic Susceptibility Patterns of Bacterial Isolates from Surgical Wounds in Abia State University Teaching Hospital (ABSUTH), Aba - Nigeria, Research Journal of Medicine and Medical Sciences, 2009; 4(2): 575-579.

20. Kireçci E, Kareem RD. Antibiotic susceptibility patterns of *P. aeruginosa* strains isolated from various clinical specimens. Sky Journal of Microbiology Research, 2014; 2(2): 013 – 017. Available online http://www.skyjournals.org/SJMR ISSN 2315-876X.

21. Rajat RM, Ninama GL, Mistry K, Parmar R, Patel K, Vegad MM. Antibiotic resistance pattern in *Pseudomonas aeruginosa* species isolated at a tertiary care hospital, Ahmadabad. National Journal of Medical Research, 2012; 2(2): 156–159.

22. Chander A, Raza MS. antimicrobial susceptibility patterns of *Pseudomonas aeruginosa* clinical isolates at a tertiary care hospital in kathmandu, Nepal. Asian Journal of Pharmaceutical and Clinical Research, 2013; 6(3): 235–38.

23. Jombo GTA, Jonah P, Ayeni JA. Multidrug resistant *Pseudomonas aeruginosa* in contemporary medical practice: findings from urinary isolates at a Nigerian University Teaching Hospital. Nigerian Journal of Physiological Sciences, 2008; 23: 105- 109.

24. Rajeevan S, Ahmad SM, Jasmin PT. Study of prevalence and antimicrobial susceptibility pattern in blood isolates from a tertiary care hospital in North Kerala, India. International Journal of Current Microbiology and Applied Sciences, (2014; 3(4): 655-662

25. Zahra T, Moniri R. "Detection of ESBLs and MDR in *Pseudomonas aeruginosa* in a Tertiary-Care Teaching Hospital," Iranian Journal of Clinical Infectious Diseases, 2011, 6(1) 18- 23

26 Sivaraj S, Murugesan P, Muthuvelu S, Purusothaman S, Silambarasan A. Comparative study of *Pseudomonas aeruginosa* isolate recovered from clinical and environmental samples against antibiotics. International Journal of Pharmacy and Pharmaceutical Sciences, 2012; 4 (3): 103- 107

27. Okonko IO, Soleye FA, Amusan TA, Ogun AA, Ogunnusi TA, Ejembi J. Incidence of Multi-Drug Resistance (MDR) Organisms in Abeokuta, Southwestern Nigeria. Global Journal of Pharmacology, 2009; 3(2): 69-80

28. Lister PD, Wolter DJ, Hanson ND. Antibacterial-Resistant *Pseudomonas aeruginosa*: Clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clinical Microbiology Reviews, 2009; 22(4): 582–610.